Beyond Bones
Vitamin D is widely known for its role in calcium homeostasis and bone mineralisation. However, the discovery of vitamin D receptors (VDR) in virtually every cell type of the immune system — including monocytes, macrophages, dendritic cells, T lymphocytes, and B lymphocytes — revealed that its biological functions extend far beyond skeletal health. Vitamin D is now recognised as a pleiotropic hormone with significant immunomodulatory properties.
Innate Immunity: First-Line Defence
When monocytes and macrophages encounter pathogens via toll-like receptors (TLRs), the activated signalling cascade upregulates expression of the enzyme CYP27B1, which converts circulating 25-hydroxyvitamin D [25(OH)D] into its active form, 1,25-dihydroxyvitamin D [1,25(OH)₂D], locally within the cell. Active vitamin D then induces the production of cathelicidin (LL-37) and β-defensin 2 — antimicrobial peptides that directly kill bacteria, mycobacteria, and enveloped viruses. This pathway was first elucidated in the context of tuberculosis, where vitamin D deficiency was associated with impaired mycobacterial killing.
Adaptive Immunity: Tuning the Response
Vitamin D exerts predominantly tolerogenic effects on adaptive immunity. It suppresses Th1 and Th17 pro-inflammatory cytokine production (IFN-γ, IL-17, IL-22), promotes Th2 responses, and — critically — enhances the differentiation and function of regulatory T cells (Tregs). Tregs are essential for preventing autoimmune reactions and maintaining immune tolerance to self-antigens and commensal microbiota. Vitamin D also inhibits B-cell proliferation and immunoglobulin secretion, and promotes a tolerogenic phenotype in dendritic cells by suppressing co-stimulatory molecule expression.
Clinical Associations
Observational studies consistently link low serum 25(OH)D with increased incidence and severity of autoimmune conditions: multiple sclerosis, type 1 diabetes, rheumatoid arthritis, and — importantly for gut health — inflammatory bowel disease. In IBD, vitamin D deficiency is common (40–70% prevalence in Crohn's disease cohorts) and correlates with disease activity, hospitalisation rates, and surgical risk. However, interventional trials have produced mixed results: the VITAL trial and the D-Health trial found limited evidence that vitamin D supplementation prevents autoimmune disease in replete populations, while trials in deficient IBD patients suggest benefit in reducing relapse rates.
Interpretation Challenges
The discrepancy between compelling observational data and inconsistent trial outcomes reflects several confounders: baseline vitamin D status varies enormously between study populations; optimal dosing and target serum levels remain debated (the Endocrine Society recommends 30 ng/mL or above, while some researchers argue for 40 ng/mL or above for immunological benefit); and the chronic, multifactorial nature of autoimmune disease means that correcting a single deficiency may be insufficient in isolation. What is clear is that maintaining adequate vitamin D status is a biologically plausible and low-risk component of immune health — even if it is not a silver bullet.